Publication:
Door-to-needle times in patients treated by on-site and off-site on-call neurologists. PRISA study.

dc.contributor.authorGallardo-Tur, A
dc.contributor.authorCarazo-Barrios, L
dc.contributor.authorde la Cruz-Cosme, C
dc.date.accessioned2023-05-03T15:13:42Z
dc.date.available2023-05-03T15:13:42Z
dc.date.issued2021-09-17
dc.description.abstractHospital on-call neurology shifts are frequently on-site, but some on-call services may be off-site or mixed. Intravenous tissue plasminogen activator (tPA) is one of the main reperfusion treatments for acute ischaemic stroke (AIS). This study assesses door-to-needle times (DNT) when the neurologist is on-site or off-site. We performed a prospective, observational study from 2012 to 2017, including patients with AIS and treated with tPA. Data were collected on sex, age, door-to-scan time, scan-to-needle time, and DNT. The on-duty neurologist was on-site from 08:00 to 20:00, and on call but off-site from 20:00 to 8:00. Three groups were formed: on-site, off-site, and off-site with resident present. Our sample included 138 patients. The mean age was 69.7 years, and 45.7% of patients were women. Ninety-six patients were admitted during the on-site shift, 25 during the off-site shift, and 17 during the off-site-resident present shift. Patients admitted during the on-site and off-site shifts presented DNTs of 59 and 72 minutes, respectively (P =  .003). DNTs were 59, 74, and 68 minutes (P =  .001), respectively, for the on-site, off-site, and off-site-resident present shifts; the difference between DNTs for on-site and off-site shifts was statistically significant. No differences were observed between DNTs according to time of day (morning, afternoon, or night), or between weekdays and weekends. DNT is influenced by whether the on-duty neurologist is on- or off-site at the time of code stroke activation. The presence of a neurology resident can reduce DNT.
dc.identifier.doi10.1016/j.nrleng.2019.08.004
dc.identifier.essn2173-5808
dc.identifier.pmid34544671
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.nrleng.2019.08.004
dc.identifier.urihttp://hdl.handle.net/10668/22453
dc.issue.number7
dc.journal.titleNeurologia
dc.journal.titleabbreviationNeurologia (Engl Ed)
dc.language.isoen
dc.organizationHospital Universitario Virgen de la Victoria
dc.organizationHospital Universitario Virgen de la Victoria
dc.page.number543-549
dc.pubmedtypeJournal Article
dc.pubmedtypeObservational Study
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectActivador tisular del plasminógeno recombinante
dc.subjectDoor-to-needle time
dc.subjectIctus
dc.subjectIntravenous thrombolysis
dc.subjectRecombinant tissue plasminogen activator
dc.subjectStroke
dc.subjectTiempo puerta-aguja
dc.subjectTrombólisis intravenosa
dc.subject.meshAged
dc.subject.meshBrain Ischemia
dc.subject.meshChild
dc.subject.meshEmergency Service, Hospital
dc.subject.meshFemale
dc.subject.meshFibrinolytic Agents
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshNeurologists
dc.subject.meshProspective Studies
dc.subject.meshStroke
dc.subject.meshThrombolytic Therapy
dc.subject.meshTime-to-Treatment
dc.subject.meshTissue Plasminogen Activator
dc.titleDoor-to-needle times in patients treated by on-site and off-site on-call neurologists. PRISA study.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number37
dspace.entity.typePublication

Files